Oocyte maturation work in fertility laboratory

NMN and fertility: in vitro oocyte rescue rose from 28.8% to 50.7%

NMN shows consistent promise in animal studies for improving oocyte quality and ovarian function, but human evidence remains limited to safety data and early surrogate markers rather than pregnancy or live-birth outcomes. Tolerability trials report no consistent serious adverse events at doses up to 900 mg per day for 60 days. Anyone considering NMN as a fertility adjunct should discuss it with a fertility clinician before starting, particularly around the timing of assisted reproductive technology.

TL;DR:

  • Human trials show NMN is well tolerated at doses up to 900 mg daily for two months, but no evidence yet confirms it improves pregnancy rates.
  • In laboratory studies, NMN restores ovarian NAD+ levels, improves mitochondrial structure, and increases follicle counts in aged mice, with limited human translation.
  • Current clinical trials are evaluating NMN’s impact on embryo development and pregnancy outcomes, but results are pending, and surrogate markers remain only indirect indicators.
  • There is a significant knowledge gap regarding NMN’s safety during pregnancy and potential long-term effects on offspring, so cessation is advised upon pregnancy confirmation.
  • Fertility clinicians generally consider NMN investigational; treatment should involve professional guidance, product quality checks, and clear communication with healthcare providers.
Vivetus
Explore NMN For Healthy Aging
Vivetus offers scientifically backed dietary supplements for people seeking healthy aging, vitality, and informed nutritional support.
Visit Vivetus

Table of Contents

What animal and laboratory studies say about NMN and ovarian function

Ovarian ageing tracks closely with a decline in NAD+, a molecule cells need to generate energy and repair DNA. Oocytes are unusually dependent on healthy mitochondria: an egg cell carries a large mitochondrial payload that must support the entire early embryo before the embryo’s own genome takes over. When NAD+ falls, mitochondrial function in the oocyte falters, and that decline is a proposed mechanism behind reduced egg quality with age.

NMN is a direct precursor to NAD+. Supplying it to cells is intended to restore NAD+ levels and, in turn, support the enzymes that depend on it for energy production and DNA repair. This is the biological rationale that has driven fertility-focused NMN research, and it is a mechanism, not a guarantee of clinical benefit.

The most consistent evidence for this pathway comes from mouse studies. Research on aging female mice found that NMN supplementation restored ovarian NAD+ levels, improved mitochondrial ultrastructure, increased follicle counts and improved markers of oocyte quality, alongside reduced inflammatory signalling in ovarian tissue. These findings have been broadly reproduced across several rodent models, which is one reason researchers have moved toward testing NMN in early human studies.

Separately, animal work in chemotherapy-damaged ovaries has shown similar patterns: NMN appears to help preserve follicle development and oocyte quality after treatments known to accelerate ovarian ageing. That points to a possible use beyond age-related decline alone, though this remains preclinical.

Preclinical findings that recur across mouse studies include:

  • Restored ovarian NAD+ levels after NMN supplementation.
  • Improved mitochondrial ultrastructure within oocytes.
  • Increased follicle counts and reduced follicular atresia (the natural loss of immature follicles).
  • Better embryo development metrics measured after fertilisation in laboratory settings.

Preclinical mouse studies show NMN restores ovarian NAD+, improves mitochondrial structure, increases follicle counts and improves oocyte quality in aged mice. That consistency across independent rodent studies is what has justified moving the question into human research, even though mouse ovarian biology and human ovarian biology are not identical.

The limitations matter as much as the findings. Mice are not small humans: their reproductive cycles are far shorter, their follicle reserves behave differently, and the doses used in rodent studies are often scaled to body weight in ways that do not translate cleanly to a safe or practical human oral dose. Mouse studies also tend to measure structural and biochemical markers, such as mitochondrial appearance or follicle counts, rather than the outcomes that matter to someone trying to conceive: a viable pregnancy and a healthy birth. A supplement can improve a laboratory marker in an animal model without moving the needle on the outcome a patient actually cares about. That gap between mechanism and outcome is exactly what human trials are now trying to close.

Human data so far: safety trials, in vitro reports and registered fertility trials

Human research on NMN and fertility exists in three distinct forms, and it helps to keep them separate because they answer different questions: is NMN safe to take, does it change egg or embryo quality in a laboratory setting, and does it improve the chance of a pregnancy. Only the first of these three questions currently has a reasonably solid answer.

Safety and tolerability trials are the most mature evidence available. Multicentre randomised controlled trials have tested oral NMN at doses up to 900 mg per day for 60 days and reported that it was generally well tolerated, with no consistent pattern of serious adverse events. These trials were not designed around fertility outcomes, so they tell us about general tolerability rather than reproductive safety specifically, but they are the backbone of current dosing decisions in fertility-focused pilot studies.

The most fertility-specific human data so far comes from a 2026 clinical abstract examining germinal-vesicle rescue, a laboratory technique used to mature certain immature egg cells retrieved during fertility treatment. Researchers reported that adding NMN in vitro increased the rescue rate from 28.8% to 50.7% in oocytes from women with a poor prognosis, a statistically significant difference. That is a meaningful signal, but it measures a laboratory maturation rate in a specific, difficult patient group, not a pregnancy or birth outcome, and it comes from a single abstract rather than a full published trial with longer follow-up.

Illustration of in vitro oocyte rescue process

Registered clinical trials are now testing NMN directly in IVF settings. One randomised, double-blind, placebo-controlled trial, NCT06426355, is recruiting women with diminished ovarian reserve to receive 600 mg per day of NMN for two to five months ahead of IVF or ICSI treatment. Its primary outcomes include clinical pregnancy rate and embryo development metrics, which makes it one of the trials most likely to answer whether NMN affects outcomes patients actually care about.

Key distinctions worth holding onto while this evidence matures:

  • Safety trials show tolerability, not fertility benefit.
  • The 2026 abstract shows an in vitro laboratory improvement, not a pregnancy outcome.
  • Registered IVF trials are still recruiting or in progress, with results not yet published.
  • Oocyte and embryo quality markers are surrogate endpoints: they often correlate with pregnancy chances but do not guarantee them.
Evidence type What was tested Dose and duration What it shows
Human safety RCTs General tolerability Up to 900 mg/day for 60 days No consistent serious adverse events
2026 clinical abstract Germinal-vesicle rescue in vitro Laboratory addition of NMN Rescue rate rose from 28.8% to 50.7%
Registered IVF trial (NCT06426355) Clinical pregnancy rate, embryo quality 600 mg/day for 2 to 5 months Recruiting; results pending

The practical takeaway is that surrogate endpoints such as oocyte maturation rates or embryo grading are useful signals for researchers deciding whether a larger trial is worth running, but they are not interchangeable with a clinical pregnancy or a live birth. Many interventions in reproductive medicine have improved a laboratory marker without translating into more babies born, which is precisely why the ongoing IVF trials matter more than the in vitro data collected so far.

What we know about NMN tolerability, typical doses used in fertility studies and unknowns for pregnancy

Tolerability data for NMN itself is more established than its fertility-specific evidence. Human trials have tested oral doses up to 900 mg per day for 60 days without a consistent pattern of serious adverse events, which is reassuring for short-term use in otherwise healthy adults. Fertility-focused pilot studies have generally worked within or below that range, with the registered NCT06426355 trial using 600 mg per day for two to five months, and other small pilot designs exploring doses up to 900 mg per day.

Formulation affects how much of that dose actually reaches the bloodstream. Trial data indicates that particle size and crystalline form influence measured NAD+ increases, so two products listing the same milligram amount on the label will not necessarily behave the same way once swallowed. This is one of the more overlooked variables in NMN research and a reason product quality is worth scrutinising, a point covered in more detail in a dedicated guide to buying NMN.

What remains genuinely unknown is more important than what is established. No published human trial has examined NMN’s effects during pregnancy itself, and reproductive safety data covering offspring outcomes in humans are lacking. Long-term effects of sustained NMN use on reproductive tissue have not been studied in humans beyond the 60-day tolerability window. Anyone actively pursuing conception, and particularly anyone already pregnant, is in a data gap that current trials have not filled.

Practical steps to take before starting NMN for fertility purposes:

  1. Confirm with a fertility clinician whether NMN fits your specific diagnosis and treatment timeline.
  2. Check the product’s purity testing and formulation, since particle form affects absorption.
  3. Avoid starting or continuing NMN once pregnancy is confirmed, given the absence of pregnancy safety data.
  4. Time any supplementation around stimulation cycles only with your clinic’s agreement, not independently.
  5. Keep a symptom log if you do start, so any change can be reported and reviewed with your clinician.

Pro Tip: Ask your fertility clinic whether they are aware of the registered NMN trials currently recruiting, such as NCT06426355; some clinics may be able to refer eligible patients directly.

More detail on tolerability data and dosing patterns, including how trial adverse events were tracked, is available in this breakdown of human NMN safety data.

How fertility clinicians currently regard NMN and how to talk to your clinic about it

Most fertility specialists currently treat NMN as investigational rather than as an established part of a treatment plan. The registered trials testing it in IVF settings exist precisely because the question has not been answered yet, and a clinician who takes a cautious stance is reflecting the state of the evidence rather than dismissing it out of hand.

Where a clinic is open to NMN as an adjunct, monitoring tends to focus on markers that are already part of standard fertility assessment: anti-Müllerian hormone (AMH), antral follicle count (AFC), the number of oocytes retrieved during a cycle, and embryo quality grading. Tracking these before and after a period of supplementation gives a clinic something concrete to review, even though none of these markers is a substitute for a pregnancy outcome. Timing also matters: if NMN is used, most current pilot protocols run it for two to five months ahead of a stimulation cycle, mirroring the duration used in the NCT06426355 trial design, rather than starting or stopping close to egg retrieval.

Registered IVF trials testing NMN, such as NCT06426355, use a 600 mg daily dose for two to five months and measure clinical pregnancy rate as a primary outcome. That trial design gives a sense of the timeframe clinicians are currently working with when NMN comes up in conversation.

NMN sits alongside other supplements with a longer track record in fertility support, including coenzyme Q10 and folate, both of which have more established roles in supporting egg quality and early pregnancy health. Where NMN might fit, according to the underlying rationale, is as one part of a broader metabolic approach addressing mitochondrial function, rather than a replacement for these better-established measures or for lifestyle factors such as sleep, weight and smoking status, which continue to carry stronger evidence for fertility outcomes overall. A useful primer on the underlying NAD+ biology, including how it interacts with these other pathways, is available in this explainer on NAD+ supplementation.

Questions worth raising directly with a fertility team:

  • Does my diagnosis (for example, diminished ovarian reserve) match the population studied in current NMN trials?
  • Would NMN interact with my current stimulation protocol or medication plan?
  • Is there a registered trial I could be eligible to join instead of using an over-the-counter product?
  • What markers would we track, and over what timeframe, if I did use it?

Potential interactions between NMN and common fertility medications or supplements

There is no published human data specifically testing NMN alongside common fertility medications such as gonadotropins, clomiphene or letrozole, so any interaction risk is currently unknown rather than ruled out. This absence of data is a reason for caution, not reassurance.

NMN is often taken alongside other supplements marketed for reproductive health, including CoQ10, myo-inositol and prenatal vitamins. No trial has systematically tested these combinations for interaction effects, positive or negative. Because NMN raises NAD+ availability and several of these other compounds act on separate metabolic pathways, a clinician is better placed than a product label to judge whether stacking supplements makes sense for a specific treatment plan.

The safest working assumption, given the data gap, is to disclose every supplement being taken, NMN included, to the fertility team managing a stimulation cycle or IVF protocol. This is standard practice for any supplement during active fertility treatment, and it applies just as much to NMN as to anything already better known in this space.

Limitations and gaps in current research on NMN for fertility

The evidence base for NMN and fertility has three consistent weak points. First, almost all of the strongest mechanistic evidence comes from mouse studies, and species differences in reproductive biology mean those findings do not automatically transfer to humans. Second, the most fertility-specific human data available, the 2026 germinal-vesicle rescue abstract, measures a laboratory maturation outcome in a narrow patient group rather than a pregnancy or live birth. Third, no completed human trial has yet reported pregnancy or live-birth outcomes following NMN supplementation, which means the registered trials currently recruiting, including NCT06426355, are still the first wave of evidence that could answer this properly.

There is also a formulation gap: trials have used different NMN forms and particle sizes, and since bioavailability varies with formulation, results from one product cannot be assumed to apply to another. Sample sizes in fertility-specific pilot work also remain small, which limits how confidently any single result can be generalised. Systematic reviews of NAD+ research consistently flag these translational gaps and call for larger, longer randomised trials with reproductive endpoints before any firm conclusion can be drawn.

Possible side effects specific to reproductive health or pregnancy

General tolerability data for NMN is reassuring within the populations studied, but that data was not collected in pregnant women or in people actively undergoing fertility treatment, so it cannot be extended to those groups with confidence. No human trial has reported on NMN’s effects during pregnancy, and no data exists on outcomes for offspring exposed to NMN in utero.

This is a genuine blind spot rather than a minor caveat. Standard practice in reproductive medicine is to avoid any supplement without established pregnancy safety data once conception is confirmed, and NMN currently falls into that category. Anyone using NMN while trying to conceive should have a clear plan, agreed with their clinician, for stopping it if a pregnancy test turns positive, rather than deciding on the point in the moment.

Considerations for NMN use in different age groups or fertility conditions

The rationale for NMN in fertility research centres on age-related decline in NAD+ and mitochondrial function, which means most current research focuses on people with diminished ovarian reserve or age-related fertility decline, such as the population targeted in the NCT06426355 trial. Extending that rationale to other fertility conditions, such as polycystic ovary syndrome or male-factor infertility, is speculative, since dedicated trials in those populations have not been published.

On the male side, NAD+ decline has a plausible role in sperm mitochondrial function, but published human trial data linking NMN specifically to sperm quality or male fertility outcomes remains limited compared with the female-fertility research already discussed. Anyone considering NMN for male fertility should treat the evidence as even earlier stage than the female-fertility research, and raise it with a fertility specialist rather than assuming the same rationale applies equally.

Ethical and oversight considerations for NMN use in fertility treatment

NMN is sold as a dietary supplement rather than as a prescription fertility treatment, which means its manufacturing standards and the oversight applied to its health claims differ from those applied to approved fertility medications. That distinction matters practically: a supplement label is not equivalent to a clinical indication, and a product being available for purchase says nothing about whether it has been shown to improve fertility outcomes.

The ethical question that matters most for patients is informed choice: understanding clearly that current evidence supports tolerability and a promising laboratory signal, not a proven fertility benefit, before deciding whether to use it during active treatment. Fertility clinics vary in how they approach patient-initiated supplement use, and the responsible path is to disclose any supplement, NMN included, before or during a treatment cycle so the clinical team can factor it into monitoring and decision-making.

Author perspective: Vivetus and Jord on NMN for fertility

The honest position on NMN and fertility is that the animal data is genuinely encouraging and the human data is genuinely early. Both things are true at once, and neither cancels the other out. What changes here is not the biology, which has looked consistent across multiple mouse studies for a few years now, but the confidence with which anyone can say it will help a specific person trying to conceive.

This company follows this literature closely because the audience buying NAD+ boosters is often the same audience asking whether NMN might help with age-related fertility decline, and giving a straight answer matters more than giving an enthusiastic one. The registered trials now running, particularly the IVF-outcome trial recruiting women with diminished ovarian reserve, are the studies that will actually settle whether the laboratory signal seen in the 2026 germinal-vesicle abstract translates into more pregnancies. Until those results are published, the most defensible stance is measured interest paired with a clear recommendation to loop in a fertility clinician before use, particularly around stimulation cycles or once a pregnancy is confirmed.

Where this company can add something concrete is product quality: purity testing and transparent formulation matter more than usual here, because trial data shows that formulation affects how much NMN actually reaches circulation. A supplement that under-delivers on its label makes even the early positive signals irrelevant. That is the standard worth asking about whatever NMN product a reader is considering, from any supplier.

— Jord

Vivetus NMN options and how to buy responsibly

Vivetus sells NMN in three formats, giving readers flexibility depending on preference and routine: Vivetus® NMN (60 x 500mg capsules) NAD+ booster, Vivetus® NMN (60 x 250mg capsules) NAD+ booster, and Vivetus® NMN poeder for those who prefer a measurable powder format. All three sit within the broader Vivetus NMN range, and each can be purchased as a one-off order or through a recurring subscription for anyone planning longer-term use under clinical guidance.

Vivetus® NMN (60 x 500mg capsules) NAD+ booster

Every product is assembled in the Netherlands using vegan, GMO-free formulations, with purity testing behind the label claims and clear ingredient transparency rather than vague blends. Orders over €50 ship free, and the site supports international shipping and multi-language customer service for readers ordering from outside its home market.

Before buying NMN for fertility purposes, keep these points in mind:

  • Confirm with your fertility clinician whether NMN is appropriate for your diagnosis and treatment timeline.
  • Disclose any NMN use to your clinic before or during an active IVF or stimulation cycle.
  • Stop use immediately once a pregnancy is confirmed, given the absence of pregnancy safety data.
  • Check formulation and purity testing, since absorption varies between products.

Readers who want a broader view of the underlying NAD+ science, or who are also considering complementary longevity ingredients such as resveratrol or quercetin, can find more detail in Vivetus’s complete guide to buying NMN. None of this replaces a conversation with a fertility specialist, and that conversation should come first.

The claims made throughout this article draw on a specific set of primary sources, listed here for anyone who wants to read the original data rather than a summary of it.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

Can NMN help with fertility?

Early evidence suggests NMN may support egg quality by improving mitochondrial function, based mainly on mouse studies and one 2026 laboratory abstract showing improved oocyte rescue rates. No completed human trial has yet shown it improves pregnancy or live-birth rates, so it should be discussed with a fertility clinician rather than used as a standalone treatment.

Can NAD+ make you more fertile?

Raising NAD+ levels is the proposed mechanism behind NMN’s effects on ovarian function, since NAD+ decline is linked to mitochondrial dysfunction in ageing oocytes. This mechanism has strong support in animal studies, but whether restoring NAD+ translates into improved human fertility outcomes is still being tested in registered clinical trials.

Does NMN raise oestrogen?

There is no published human trial data showing that NMN raises oestrogen levels. Its studied mechanism relates to NAD+ and mitochondrial function rather than direct hormonal signalling, and any hormonal effects would need dedicated trial data to confirm.

Which supplement is best for female fertility?

No single supplement is established as best, since fertility depends on many factors and the evidence base varies by ingredient. Coenzyme Q10 and folate have a longer track record in supporting egg quality and early pregnancy health, while NMN remains earlier stage, with promising preclinical data but limited human trial results so far; a fertility clinician can advise on what fits a specific diagnosis.

What NMN dose is used in fertility studies?

Registered fertility trials, including NCT06426355, have used 600 mg per day for two to five months, while general tolerability trials have tested doses up to 900 mg per day for 60 days without consistent serious adverse events. These figures reflect trial design rather than a confirmed effective dose for fertility outcomes specifically.

Regresar al blog